A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched today with an extensive integrated network ...
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies Lonza will ser...
Mabion S.A. ("Mabion"), a leading Polish CDMO specializing in the development and manufacturing of biopharmaceuticals for third parties, and Instituto de B...
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure ...
Croda is pleased to announce the appointments of Stephen Oxley as Chief Financial Officer (CFO) and Executive Director, and Dr. Thomas Riermeier as Presi...
CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and la...
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, de...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) wit...
In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1) CORE EBITDA of CHF 1.9 billion at a margin of 29.0% The CDMO...
Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing...
Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration wi...
3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies Grant enables global implementation of the ...
Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars product...
Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure As Lonza focuses on its core CDMO1 busines...
© 2025 Biopharma Boardroom. All Rights Reserved.
